

CHANGING THE WAY WE LOOK AT CANCER

Transforming medical imaging

CANCER IS A GLOBAL HEALTH PROBLEM

1 in 3 people are affected by cancer.

Cancer continues to be a leading cause of mortality and morbidity, killing 9 million people a year, globally.

MEDICAL IMAGING NEEDS IMPROVEMENT

Treatments are more successful and survival rates improve with early detection; however, today's medical imaging technologies such as ultrasound, CT, and mammography are still not able to tell you if a suspicious spot is in fact cancer, thus needing invasive biopsies to confirm.

CURRENT MEDICAL IMAGING METHODS

Currently, there are five different ways to image the body



ENTER MAGSENSE® TECHNOLOGY

patient to ionized radiation

MagSense® imaging agent technology uses bio-safe, non-radioactive magnetic nanoparticles coated with a cancer-specific targeting molecule. The nanoparticles are designed to circulate through the body and attach to cancer cells, resulting in a unique and differentiable pattern when imaged by an MRI machine.



expensive in some

countries.



IS IT CANCER?



MagSense nanoparticles attach to a cancerous tumor, giving off molecular signal.

Once the targeted MagSense® nanoparticles attach to cancer cells, they are detectable by an MRI scan. If no cancer is present, the image is different. This means instead of simply identifying a suspicious spot on a scan, MagSense can potentially identify whether in fact, that spot on the scan is cancer or not.

THE MAGSENSE DIFFERENCE



A safe and non-surgical solution to detect cancer. The nanoparticles are cleared by the liver and recycled by the body for hemoglobin production

SPECIFIC

The use of a targeted imaging agent provides molecular confirmation of the presence of cancer not just a suspicion

FASTER

Reduce time of clinical decisions and reducing the need for unnecessary biopsy procedures, enabling a faster path to treatment.

MULTIPLE APPLICATIONS

MagSense® imaging agents can be developed for many types of cancers and can be used at multiple stages of diagnosis including primary diagnosis, staging, and monitoring the effectiveness of therapy.



ON THE WAY TO IMPROVING CURRENT STANDARD OF CARE



MagSense® imaging agent technology is currently in clinical testing, focused first on HER2+ breast cancer detection in nodal staging, which allows the radiologist to see if cancer has spread to the lymph nodes.

Our preclinical research is currently focused on prostate, ovarian, and brain cancer imaging agent applications.

We are on a mission to make cancer more detectable. Join us on this exciting journey as we strive to save the lives of our loved ones.

info@imagionbio.com | imagiobio.com



